Document is current

Any future updates will be listed below

1296 Tumor-activated immune cell engagers designed to drive synthetic immunity against cancer demonstrated protease-dependent activation and robust anti-tumor activity in preclinical models

Crossref DOI link: https://doi.org/10.1136/jitc-2024-SITC2024.1296

Published Online: 2024-11-05

Published Print: 2024-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark